

CURRICULUM VITAE

BRADLEY CAMERON EKSTRAND, M.D., PH.D.

CURRENT AFFILIATION:

2003 – present: President and Staff Physician
California Cancer Care, Inc.
218 De Anza Blvd.
San Mateo, CA 94402

Telephone: (650) 341-9131

Place of Birth: Boulder, Colorado

EDUCATION:

1990-1997 Yale University School of Medicine
New Haven, Connecticut
M.D.

1990-1997 Yale University School of Medicine
Department of Pharmacology
New Haven, Connecticut
Ph.D., M.Phil.
Faculty Advisor: Dr. Eric R. Fearon

1986-1990 Stanford University
Palo Alto, California
B.S. in Chemistry

POST-DOCTORAL TRAINING:

2000-2003 Fellow in Medical Oncology
Stanford University School of Medicine
Stanford, California

1997-2000 Mount Sinai Medical Center
New York, New York
Internship and Residency in Internal Medicine

ACADEMIC APPOINTMENTS:

2003-2010 Adjunct Clinical Instructor
Division of Oncology, Department of Medicine
Stanford University School of Medicine
Stanford, CA

2002-2003 Staff Physician and Voluntary Clinical Faculty
Department of Medicine, Division of Oncology
Stanford University School of Medicine
Stanford, CA

1999-2000 Teaching Assistant, Department of Medicine
Mount Sinai School of Medicine
New York, New York

LICENSURE: California Certificate: A71243
April, 2000

BOARD American Board of Internal Medicine
CERTIFICATION: Certified in Internal Medicine (10/2000; recertified 11/2010)
Certified in Medical Oncology (11/2003)

HONORS:
June 1990 Phi Beta Kappa
Stanford University

June 1990 B.S. in Chemistry with Honors and Distinction
Stanford University

May 2001 Housestaff Teaching Award Nominee
Department of Medicine
Stanford University Medical School

March 2002 Postdoctoral Fellow Merit Award
American Society of Clinical Oncology

PROFESSIONAL SOCIETIES:

2001 – present American Society of Clinical Oncology
Member

2003 – present Association of Northern California Oncologists
Member since 2003
Board of Directors since March 2007
Secretary since January 2008

PROFESSIONAL EDUCATION:

July 2002 Workshop on Methods in Clinical Cancer Research
American Society of Clinical Oncology and
American Association for Cancer Research
Vail, Colorado

TEACHING APPOINTMENTS:

Fall 1994 Teaching Assistant, Upper Level Cell Biology course
Department of Biology
Yale College, New Haven, Connecticut
Director: Prof. Joel Rosenbaum

PUBLICATIONS:

- Govindan, R., Crowley, J., Schwartzberg, L., Kennedy, P., Williams, C., **Ekstrand, B.**, et al. (2006) Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. *J. Clin. Oncol.* **24**:4848-4854.
- Ekstrand, B.C.**, Fan, Z., Lucas, J.B., Horwitz, S.M., Breslin, S., Natkunum, Y., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. *Blood* **101**: 4285-4289.
- Ekstrand, B.C.** and Horning, S.J. (2002) Lymphocyte predominant Hodgkin's disease. *Curr. Oncol. Rep.* **4**: 424-433.
- Ekstrand, B.C.** and Horning, S.J. (2002) Hodgkin's Disease. *Blood Reviews* **16**: 111-117.
- Meyerhardt, J.A., Caca, K., **Ekstrand, B.C.**, Hu, G., Legnauer, C., Banavali, S., Look, A.T., and Fearon, E.R. (1999) Netrin-1: a candidate DCC ligand is inactivated in a subset of neuroblastomas and brain tumors. *Cell Growth Diff.* **10**: 35-42.
- Reyes-Mugica, M., Rieger-Christ, K., Ohgaki, H., **Ekstrand, B.C.**, Helie, M., Kleinman, C., Yahanda, A., Fearon, E.R., Kleihues, P., and Reale, M.A. (1997) Loss of *DCC* expression and glioma progression. *Cancer Res.* **57**: 382-386.
- Ekstrand, B.C.**, Mansfield, T.A., Bigner, S.H., and Fearon, E.R. (1995) *DCC* expression is altered by multiple mechanisms in brain tumours. *Oncogene* **11**: 2393-2402.
- Fearon, E.R., **Ekstrand, B.C.**, Hu, G., Pierceall, W.E., Reale, M.A., and Bigner, S.H. (1994) Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues. *Cold Spring Harb. Symp. Quant. Biol.* **59**: 637-643.
- Vreman, H.J., **Ekstrand, B.C.**, and Stevenson, D.K. (1993) Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. *Pediatr. Res.* **33**: 195-200.
- ABSTRACTS PRESENTED:**
- Ekstrand, B.C.**, Lucas, J.B., Horwitz, S.M., Breslin, S., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. *Proc. Amer. Soc. Clin. Oncol.* **21**: 264a
- Ekstrand, B.C.**, Bigner, S.H., and Fearon, E.R. (1995) *DCC* gene mutations and loss of expression in glioblastomas. *Proc. Amer. Assoc. Cancer Res.* **36**: 574a.

Ekstrand, B.C., Vreman, H.J., and Stevenson, D.K. (1990) Selection of heme oxygenase inhibitors based on potency and photoreactivity. *Pediatric Res.* **27**: 59a.

RESEARCH EXPERIENCE:

Ongoing experience in Phase I, II, III, and IV Clinical Pharmaceutical Trials as a Principal and/or Sub Investigator. Completed NIH Office of Human Subjects Research training module.